Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-06-05
2007-06-05
Falk, Anne-Marie (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
active
10150461
ABSTRACT:
The present invention relates to the use of nimesulide and structurally related compounds in the prevention and/or treatment of neurodegenerative conditions. It is based, at least in part, on the discovery that nimesulide exhibits a neuroprotective effect against β-amyloid induced cell death. Without being bound to any particular theory, it appears that nimesulide inhibits a non-inflammatory mechanism of neurodegeneration.
REFERENCES:
patent: 5486534 (1996-01-01), Lee et al.
patent: 5510361 (1996-04-01), Scherz et al.
patent: 5510368 (1996-04-01), Lau et al.
patent: 5545656 (1996-08-01), Loose et al.
patent: 5547975 (1996-08-01), Talley et al.
patent: 5604260 (1997-02-01), Guay et al.
patent: 5753694 (1998-05-01), Shank
patent: 5985930 (1999-11-01), Pasinetti et al.
patent: 2002/0162130 (2002-10-01), Pasinetti et al.
patent: 2164559 (1996-06-01), None
patent: 3002356 (1996-11-01), None
patent: WO 9413635 (1994-06-01), None
patent: WO 9414977 (1994-07-01), None
patent: WO 9500501 (1995-01-01), None
patent: WO 9603396 (1996-02-01), None
patent: WO 9607651 (1996-03-01), None
patent: WO 9608482 (1996-03-01), None
patent: WO 9611676 (1996-04-01), None
patent: WO 9616934 (1996-06-01), None
patent: WO 9619469 (1996-06-01), None
patent: WO 9623786 (1996-08-01), None
patent: WO 9625405 (1996-08-01), None
patent: WO 9820864 (1998-05-01), None
Gouras, GK (2001) Current theories for the molecular and cellular pathogenesis of Alzheimer's disease. Expert Reviews in Molecular Medicine, May 31, http://www-ermm.cbcu.cam.ac.uk/01003167h.htm.
Kumar et al. (1992) Basic Pathology, Fifth Edition, W.B. Saunders Company, Philadelphia, pp. 725-729.
Price et al. (1998) Genetic neurodegenerative diseases: the human illness and transgenic models. Science 282: 1079-1083.
Selkoe, DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiological Reviews 81(2): 741-766.
Xavier Rabasseda: “Nimesulide: A selective cyclooxygenase 2 inhibitor anti-inflammatory drug” Drugs of Today, vol. 32, No. 5, Jul. 1996, pp. 365-384, XP002059316.
G. Tocco et al.: Cyclooxygenase-2 (COX-2) a developmentally regulated gene that shows regiona induction to excitotoxic lesions in the rat brain Society for Neuroscience Abstracts, p. 216 XP002059317.
M. Nakayama et al.; “The immediate early gene cyclooxygenase-2 is expressed in CA 1 neurons destined for apoptotic death following global ischemia” Society for Neuroscience Abstracts, vol. 21, No. 1-3, 1995, p. 1268 XP002059318.
M. Nakayama et al.: “Cyclooxygenase-2 promotes neuronal cell death after global ischenia in rat CA1 hippocampus” Society for Neuroscience Abstracts, vol. 22, No. 1-3, 1996, p. 1670 XP002059319.
Raymund L. Zhu et al.: “Cyclooxygenase-2 is expressed in vulnerable neurons in the rat brain by kainate excitotoxicity” Society for Neuroscience Abstracts, vol. 21, No.1-3, 1995, p. 300 XP002059320.
Tianxing, Yang et al.: “Tissue-specificity of cyclooxygenase-2 promoter in transgenic mice” Journal of the American Society of Nephrology, vol. 7, No. 9, 1996, p. 1652 XP002071234.
IBC's Industry Symposium on COS-2 Inhibitors, Aug. 6-7, 1998, San Diego, CA, abstract by D Pasinetti.
Mattson, 1998, “Experimental Models of Alzheimer's Disease” Science & Medicine Mar./Apr. 16-25.
McGeer and McGeer, 1998, “Inflammation and Alzheimer's Disease Potential Use of Anti-Inflammatory Agents” Neurol. Rev.1(Suppl.):8-11.
Needleman and Isakson, 1998, “Selective Inhibition of Cyclooxygenase 2” Science & Medicine Jan./Feb.:26-35.
Lukiw and Bazan, 1997, “Cyclooxygenase-2 (COX2) RNA Message Stability in Alzheimer's Disease (AD) Neocortex” Soc. for Neurosci. Abstracts 23:2171.
Lukiw and Bazan, 1997, “Cyclooxygenase 2 RNA Message Abundance, Stability, and Hyperbariability in Sporadic alzheimer Neocortex” J. Neurosci. Res. 50:937-945.
Lundberg et al., 1997, “Nitric Oxide and Inflammation: The Answer is Blowing in the Wind” Nature Med. 3:30-31.
Crowe et al., 1997, “Apoptosis and Delayed Degeneration After Spinal Cord Injury in Rats and Monkeys” Nature Med. 3:73-76.
Adams et al., 1996, “Cyclooygenase-2 Induction in Cerebral Cortex: An Intracellular Response to Synaptic Excitation” J. Neurochem. 66:6-13.
Aisen et al., 1996, “A Pilot Study of Prednisone in Alzheimer's Disease” Dementia 7:201-206.
Anderson et al., 1996, “DNA Damage and Apoptosis in Alzheimer's Disease: Colocalization with c-Jun Immunoreactivity, Relationship to Brain Area, and Effect of Postmortem Delay” The Journal of Neuroscience 16(5):1710-1719.
Chang et al., 1996, “Prostaglandin G/H Synthase-2 (Cyclooxygenase-2) mRNA Expression is Decreased in Alzheimer's Disease” Neurobiology of Aging (17)5:801-808.
Fagarasan and Aisen, 1996, “IL-1 and Anti-Inflammatory Drugs Modulate A β cytotoxicity in PC12 cells” Brain Res. 723:231-234.
Li et al., 1996, “β-Amyloid Induces Apoptosis in Human-Derived Neurotypic SH-SY5Y Cells” Brain Research 738:196-204.
McGreer et al., 1996, “Arthritis and Anti-inflammatory Agents as Possible Protective Factors for Alzheimer's Disease:” Neurology 47:425-432.
Kaufman et al., 1996, Cox-2 “A Synaptically Induced Enzyme, is Expressed by Excitatory Neurons at Postsynaptic Sites in Rat Cerebral Cortex” Proc. Natl. Acad. U.S.A. 93:2317.
Graham et al., 1996, “Cyclooxygenase 2 is Induced in Rat Brain After Kainate Induced Seizures and Promotes Neuronal Death in CA3 Hippocampus” Soc. for Neuroscience 22:Abstr. 818.15.
Pasinetti et al., 1996, “Inflammatory Mechanisms in Neurodegeneration and Alzheimer's Disease The Role of the Complement System” Neurobiology of Aging 17(5):707-716.
Tocco et al., 1996, Soc. for Neurosci. Abstracts 22:215 (citation in previous IDS incomplete).
Yang et al., 1996, “Tissue-Specificity of Cyclooxygenase-2 Promoter in Transgenic Mice” ,J. Am. Soc. Nephrol. 7:1652. (Abstract only;citation in previous IDS inaccurately listed first name o inventor).
Aisen, 1995, “Anti-Inflammatory Therapy for Alzheimer's Disease” Dementia 9(2):173-182.
Anderson et al., 1995, “Differential Induction of Immediate Early Gene Protein in Cultured Neurons by β-Amyloid (Aβ): Association of c-Jun with Aβ-Induced Apoptosis” Journal of Neurochemistry 65(4):1487-1498.
Oda et al., 1995, “Complement and β-amyloid (Aβ) Neurotoxicity in vitro: A Model for Alzheimer's Disease” Alzheimer's Research 1:29-34.
Smale et al., 1995, “Evidence for Apoptotic Cell Death in Alzheimer's Disease” Exp. Neurol. 133:225-230.
Tsujii and DuBois, 1995, “Alterations in Cellular Adhesion and Apoptosis in Epithelial Cells Overexpressing Prostaglandin Endoperoxide Synthase 2” Cell 83:493-501.
Aisen and Davis, 1994, “Inflammatory Mechanisms in Alzheimer's Disease: Implications for Therapy” Am J. Psychiatry 151(8):1105-1113.
Anderson et al., 1994, “Increased Immunoreactivity for Jun-and Fos-Related Proteins in Alzheimer's Disease: Association with Pathology” Experimental Neurology 125:286-295.
Loo et al., 1993, “Apoptosis is Induced by β-Amyloid in Cultured Central Nervous System Neurons” Proc. Natl. Acad. Sci. USA 90:1-5.
Rogers et al., 1993, “Clinical Trial of Indomethacin in Alzheimer's Disease” Neurology 43:1609-1611.
Yamagata, 1993, “Expression of a Mitogen-Inducible Cyclooxygenase in Brain neurons: Regulation by Synaptic Activity and Glucocorticoids” Neuron 11:371-386.
Bannwarth et al., 1989, “Clinical Pharmacokinetics of Nonsteroidal Anti-inflammatory Drugs in the Cerebrospinal Fluid” Biomed. & Pharmacother 43:121-126.
Murphy et al., 1989, “Glutamate Toxicity in a Neuronal Cell Line Involves Inhibition of Cystine Transport Leading to Oxidative Stress” Neuron 2:1547-1558.
Merck Index, p. 1125,
Aisen Paul S.
Pasinetti Giulio M.
Baker & Botts LLP
Falk Anne-Marie
University of Mount Sinai School of Medicine of the City of New
LandOfFree
Treatment of neurodegenerative conditions with nimesulide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of neurodegenerative conditions with nimesulide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of neurodegenerative conditions with nimesulide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3839771